NYSE
HQL
Last Price
US $19.98
KEY FIGURES
MKT CAP
$0.6B
EPS
TTM
$6.52
PEG
TTM
0.00x
P/E
TTM
2.85x
P/S
TTM
6.78x
YIELD
10.60%
GROWTH
Revenue Y/Y
Cash Flow (DCF)
Fair Value
Market $19.98
—
Default assumptions
EBITDA Multiple
Fair Value
Market $19.98
3.90%
Default assumptions
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Tekla Life Sciences Investors carries no debt; cash flow comfortably covers obligations.
Financial risk - Healthy cash flow growth.
Tekla Life Sciences Investors has insufficient data to evaluate this check.
Financial stability - Healthy debt to equity ratio.
Tekla Life Sciences Investors's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Tekla Life Sciences Investors has insufficient data to evaluate this check.
Financial stability - Net debt/EBITDA.
Tekla Life Sciences Investors has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Tekla Life Sciences Investors earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Tekla Life Sciences Investors's profit margin has increased (237.32%) in the last year from 98.40% to 331.92%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Tekla Life Sciences Investors's short-term assets of $1.25M exceed its short-term liabilities of $720.90K
Increasing performance - ROA.
Tekla Life Sciences Investors's return on assets of 35.18% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Tekla Life Sciences Investors's return on equity of 36.89%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Tekla Life Sciences Investors's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
Tekla Life Sciences Investors had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings
Decreasing performance - Free cash flow.
Tekla Life Sciences Investors has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Tekla Life Sciences Investors has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Tekla Life Sciences Investors's yearly earnings has increased 0.35% since last year from $85.30M to $85.59M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
Tekla Life Sciences Investors's yearly revenue has decreased -0.35% since last year from $86.69M to $86.39M, signaling decreasing performance
Increasing performance - ROIC.
ROIC 35.18% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
Tekla Life Sciences Investors's 3-year revenue CAGR of 39.44% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Tekla Life Sciences Investors had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Tekla Life Sciences Investors had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Tekla Life Sciences Investors has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Tekla Life Sciences Investors has an earnings yield of 33.85%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Undervalued - EBITDA valuation.
Tekla Life Sciences Investors is undervalued relative to its fair value price of 20.76 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Tekla Life Sciences Investors has an EV/EBITDA ratio of 2.95x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Tekla Life Sciences Investors has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Tekla Life Sciences Investors has a price-to-book ratio of 1.04x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Tekla Life Sciences Investors has a price-to-sales ratio of 9.80x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
36.89%
Return on equity
ROIC: 35.18%
Valuation History
2.9X
Price to Earnings
EV/EBITDA: 3.0X
Cash flow
Profit margin
17.20%
(FY vs FY)
EBITDA Y/Y
-7.00%
(FY vs FY)
Cash flow Y/Y
0.00%
(FY vs FY)
EARNINGS FV (GRAHAM)
Fair Value
Market $19.98
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.